Galapagos’ alliance strategy combines novel targets and candidate drugs discovered by Galapagos with patient expertise from Galapagos’ pharma partners. Galapagos runs these programs until candidate drug, Phase 1 or Phase 2, at which point the partner has the option to license the program.
Galapagos is progressing around 15 alliance programs under its seven alliances with five top pharma companies. Since its first risk/reward sharing alliance with GSK in 2006, Galapagos has received more than $530 million in payments, indicating the substantial delivery on alliance objectives.
|Rheumatoid arthritis/Crohn's disease||AbbVie||2012|
Galapagos’ seven strategic pharma alliances